Emerich Dwaine F, Hemendinger Richelle, Halberstadt Craig R
Sertoli Technologies, Inc, Cranston RI 02921, USA.
Cell Transplant. 2003;12(4):335-49. doi: 10.3727/000000003108746894.
There is a renewed enthusiasm for the potential of cellular transplantation as a therapy for numerous clinical disorders. The revived interest is largely due to the unprecedented success of the "Edmonton protocol," which produced a 100% cure rate for type I diabetics following the transplantation of human islet allografts together with a modified immunosuppressive regimen. While these data provide a clear and unequivocal demonstration that transplantation is a viable treatment strategy, the shortage of suitable donor tissue together with the debilitating consequences of lifelong immunosuppression necessitate a concerted effort to develop novel means to enable transplantation on a widespread basis. This review outlines the use of Sertoli cells to provide local immunoprotection to cografted discordant cells, including those from xenogeneic sources. Sertoli cells are normally found in the testes where one of their functions is to provide local immunologic protection to developing germ cells. Isolated Sertoli cells 1) engraft and self-protect when transplanted into allogeneic and xenogeneic environments, 2) protect cografted allogeneic and xenogeneic cells from immune destruction, 3) protect islet grafts to reverse diabetes in animal models, 4) enable survival and function of cografted foreign dopaminergic neurons in rodent models of Parkinson's disease (PD), and 5) promote regeneration of damaged striatal dopaminergic circuitry in those same PD models. These benefits are discussed in the context of several potential underlying biological mechanisms. While the majority of work to date has focused on Sertoli cells to facilitate transplantation for diabetes and PD, the generalized ability of these unique cells to potently suppress the local immune environment opens additional clinical possibilities.
细胞移植作为治疗多种临床疾病的一种疗法,正重新引发人们的热情。这种兴趣的复苏很大程度上归功于“埃德蒙顿方案”取得的前所未有的成功,该方案在人类胰岛同种异体移植结合改良免疫抑制方案后,使I型糖尿病的治愈率达到了100%。虽然这些数据清楚明确地表明移植是一种可行的治疗策略,但合适供体组织的短缺以及终身免疫抑制带来的不良后果,使得必须齐心协力开发新方法,以实现广泛的移植。本综述概述了利用支持细胞为共移植的不匹配细胞(包括来自异种来源的细胞)提供局部免疫保护。支持细胞通常存在于睾丸中,其功能之一是为发育中的生殖细胞提供局部免疫保护。分离的支持细胞:1)移植到同种异体和异种环境中时能植入并自我保护;2)保护共移植的同种异体和异种细胞免受免疫破坏;3)在动物模型中保护胰岛移植以逆转糖尿病;4)使共移植的外来多巴胺能神经元在帕金森病(PD)啮齿动物模型中存活并发挥功能;5)促进同一PD模型中受损纹状体多巴胺能神经回路的再生。在几种潜在的潜在生物学机制背景下讨论了这些益处。虽然迄今为止的大部分工作都集中在利用支持细胞促进糖尿病和PD的移植,但这些独特细胞有效抑制局部免疫环境的普遍能力开启了更多临床可能性。